Cyclacel Pharmaceuticals Files 8-K: Material Agreement & Equity Sales
Ticker: BGMSP · Form: 8-K · Filed: Sep 4, 2025 · CIK: 1130166
Sentiment: neutral
Topics: material-agreement, equity-sale, filing
Related Tickers: CYCC
TL;DR
Cyclacel Pharma filed an 8-K on 9/4/25 for a material agreement and equity sales. Keep an eye on this.
AI Summary
On September 4, 2025, Cyclacel Pharmaceuticals, Inc. filed an 8-K report detailing a material definitive agreement. The filing also covers unregistered sales of equity securities and includes financial statements and exhibits. The company is incorporated in Delaware and its fiscal year ends on December 31.
Why It Matters
This 8-K filing indicates significant corporate activity, including a new material agreement and equity transactions, which could impact the company's financial standing and future operations.
Risk Assessment
Risk Level: medium — The filing involves material definitive agreements and unregistered sales of equity, which can introduce financial and operational risks.
Key Numbers
- 20250904 — Filing Date (Date of Report)
- 1231 — Fiscal Year End (Company's fiscal year ends on December 31)
- 0-50626 — Commission File Number (SEC File Number)
Key Players & Entities
- Cyclacel Pharmaceuticals, Inc. (company) — Registrant
- 0001130166 (company) — Central Index Key
- 2834 (company) — Standard Industrial Classification (Pharmaceutical Preparations)
- 0001641172-25-026571 (dollar_amount) — Accession Number
- 200 CONNELL DRIVE (dollar_amount) — Business Address Street 1
- SUITE 1500 (dollar_amount) — Business Address Street 2
- BERKELEY HEIGHTS (dollar_amount) — Business Address City
- NJ (dollar_amount) — Business Address State
- 07922 (dollar_amount) — Business Address Zip
- 908-517-7330 (dollar_amount) — Business Phone
FAQ
What is the nature of the material definitive agreement entered into by Cyclacel Pharmaceuticals, Inc. on September 4, 2025?
The filing states that an "Entry into a Material Definitive Agreement" is an item of disclosure, but the specific details of the agreement are not provided in this excerpt.
What type of equity securities were sold on an unregistered basis by Cyclacel Pharmaceuticals, Inc.?
The filing indicates "Unregistered Sales of Equity Securities" as an item of disclosure, but the specific type and details of these securities are not detailed in this excerpt.
When is Cyclacel Pharmaceuticals, Inc.'s fiscal year end?
Cyclacel Pharmaceuticals, Inc.'s fiscal year ends on December 31.
What is the business address of Cyclacel Pharmaceuticals, Inc.?
The business address is 200 CONNELL DRIVE, SUITE 1500, BERKELEY HEIGHTS, NJ 07922.
What is the Commission File Number for Cyclacel Pharmaceuticals, Inc.?
The Commission File Number for Cyclacel Pharmaceuticals, Inc. is 0-50626.
Filing Stats: 632 words · 3 min read · ~2 pages · Grade level 10.6 · Accepted 2025-09-04 16:00:39
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share CYCC The Nasdaq Capital M
Filing Documents
- form8-k.htm (8-K) — 43KB
- ex10-1.htm (EX-10.1) — 49KB
- form8-k_001.jpg (GRAPHIC) — 7KB
- 0001641172-25-026571.txt ( ) — 327KB
- cycc-20250904.xsd (EX-101.SCH) — 4KB
- cycc-20250904_def.xml (EX-101.DEF) — 26KB
- cycc-20250904_lab.xml (EX-101.LAB) — 36KB
- cycc-20250904_pre.xml (EX-101.PRE) — 25KB
- form8-k_htm.xml (XML) — 6KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: September 4, 2025 Cyclacel Pharmaceuticals, Inc. By: /s/ Datuk Dr. Doris Wong Sing Ee Name: Datuk Dr. Doris Wong Sing Ee Title: Chief Executive Officer and Executive Director 3